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SI Materials and Methods
Bacterial Culture and Strain Construction. All strains used in this
study are detailed in Table S3. E. coli strains used for cloning were
grown in LB (37 °C) supplemented with 50 μg·mL−1 kanamycin
(Kan) or 100 μg·mL−1 ampicillin when required. All strains were
constructed using standard cloning techniques. Primers are listed in
Table S4. Site-directed mutagenesis was performed using the PCR-
sewing method. All constructs were verified by DNA sequencing.
All B. abortus strains were grown on either Schaedler agar
(Difco) supplemented with 5% defibrinated bovine blood (SBA)
or Brucella broth (Difco) and grown at 37 °C supplemented with
5% CO2 [with the exception of the ctrA(V148F) temperature-
sensitive strain, which was grown at 30 °C]. When needed, for
maintenance of plasmids, B. abortus strains were supplemented
with 50 μg·mL−1 Kan to maintain selection. All studies on live
B. abortus strains were performed at the University of Chicago
Howard T. Ricketts Laboratory under BSL3 conditions per CDC
rules and regulations.
Overexpression of chpT and cpdR(WT) and cpdR(D52A) was
performed by cloning into the replicating, IPTG-inducible vector
pSRK (70). Expression was induced by the addition of 2 mM IPTG.
Purification of His6-Tagged Proteins Expressed in E. coli. Genes
encoding proteins to be overexpressed were cloned into pET28a
(Novagen) and expressed in Rosetta E. coli(DE3). All proteins
used in the kinase and phosphotransfer assays were purified
using the following method: For each strain, a 10-mL overnight
culture was used to inoculate a 250-mL culture of Terrific Broth
supplemented with Kan50 and grown (37 °C, 220 rpm) until
OD600 reached 0.7–0.8. Cultures were then induced with 1 mM
IPTG and grown for 4–6 h at 20 °C, before being pelleted by
centrifugation in a Sorvall F10S-6 × 500y rotor at 6,000 × g for
10 min. Cell pellets were stored at −20 °C until purification. For
purification, cell pellets were thawed and suspended in 10 mL of
lysis buffer [25 mM Tris pH 7.6, 125 mM NaCl, 10 mM imidazole,
1% (vol/vol) Triton X-100, 5 μg·mL−1 DNaseI, 50 μg·mL−1 PMSF,
and 3 mg·mL−1 lysozyme]. Samples were incubated for an hour
and pelleted to remove insoluble cell debris. Lysates were added
to a column containing 4 mL of Chelating Sepharose FF (GE)
charged with Ni2+ and equilibrated with column buffer (25 mM
Tris pH 7.6, 125 mM NaCl, and 10 mM imidazole). CckA and
REC domain proteins were dialyzed overnight at 4 °C against
storage buffer (25 mM Tris pH 7.6, 125 mM NaCl, and 50%
glycerol) and stored at −20 °C. After purification ChpT proteins
were dialyzed against 25 mM Tris pH 7.6 and 125 mM NaCl and
aliquots were snap-frozen in liquid nitrogen and stored at −80 °C.
For protein crystallography 50 mL of overnight E. coli cultures
were added to 2 L of LB, grown with shaking (37 °C, 220 rpm)
until OD600 reached 0.6, and induced with 1 mM IPTG. After 4 h,
cells were pelleted as above and stored at −20 °C until purifica-
tion. For purification, cells were thawed and resuspended in
50 mL buffer A (25 mM Tris pH 7.6 and 125 mMNaCl) and lysed
by three passages through a French pressure cell. Cells were
clarified by a 20,000 × g spin and lysates were loaded onto a
column loaded with 10 mL chelating resin listed above, equili-
brated in buffer A. Resin was washed five times with three column
volumes of column buffer and eluted with elution buffer (25 mM
Tris pH 7.6, 125 mM NaCl, and 500 mM Imidazole). All proteins
were dialyzed against 2 L of dialysis buffer (25 mM Tris pH 7.6
and 125 mM NaCl), concentrated using 3-kDa (molecular weight
cut-off, MWCO) centrifugal filters (Amicon; Millipore). All pro-
teins were assayed for purity by 14% SDS/PAGE.
In Vitro Kinase and Phosphotransfer Assays. All kinase and phos-
photransfer reactions were carried out in 1× kinase buffer (10×
kinase buffer, 250 mM Tris pH 7.6, 500 mM KCl, 10 mM MgCl2,
10 mM MnCl2, 10 mM CaCl2, and 10 mM DTT) (59). Reactions
were incubated at room temperature and were initiated by ad-
dition of an ATP mix (25 μM ATP and 0.3 μM [γ-32P]ATP). At
the indicated times, aliquots were removed and stopped by ad-
dition to an equal volume of SDS-loading buffer. In phospho-
transfer reactions, CckA was allowed to autophosphorylate for
30 min before addition to ChpT and or CpdR/CtrA. All proteins
were used at a final concentration of 5 μM. Samples were re-
solved by 15% SDS/PAGE. The dye front, which contains un-
incorporated ATP, was removed and gels were subsequently
exposed for 2–4 h on a phosphor screen before visualization
using a FX Pro Plus Molecular Imager (Bio-Rad).
Phosphotransfer profiling experiments were performed fol-
lowing previously published methods (20, 21). Briefly, CckA was
allowed to autophosphorylate for 30 min and incubated with
either ChpT or buffer for 5 min before proceeding with phos-
photransfer reactions. CckA or CckA–ChpT solutions were in-
cubated with each REC domain for 15 s before reactions were
stopped by addition of an equal volume of SDS/PAGE buffer.
The final concentration of proteins in these profiling experi-
ments was 2.5 μM CckA, 6.6 μM ChpT, and 12.5 μM of each
REC domain. AcP labeling of REC domains was performed as
previously described (20, 59). Reactions were resolved by run-
ning on a Precast Criterion 18% SDS/PAGE gel (Bio-Rad) and
visualized as above.
Crystallization of ChpT and the ChpT–CtrA Complex. Proteins were
purified following the methods described above. All crystalliza-
tion conditions used the hanging drop vapor diffusion technique.
The final concentration of proteins used for screening for the
ChpT–CtrA complex were 8.4 mg·mL−1 ChpT and 5.3 mg·mL−1
CtrA. The structure of ChpT alone was obtained by mixing
CckAsoluble (20 mg·mL
−1 final) and ChpT (4.7 mg·mL−1 final) in
solution after purification and concentration. Initial screening
was performed in a 96-well plate format using a Mosquito robot
(TTP Labtech), which mixed 0.1 μL of protein solution and
0.1 μL of the crystallization solution and subsequently equili-
brated this drop against 75 μL of crystallization buffer. Com-
mercial crystallization kits were used for initial crystallization
screening (Nextel Suites; Qiagen). After manual refinement in
24-well plates (Hampton Research) the best crystals for ChpT–
CtrA were obtained in the following crystallization buffer at
19 °C: 0.1 M Hepes pH 7.0 and 8% (wt/vol) PEG 8000. The best
crystals for ChpT alone were obtained after seeding using a horse
hair in the following crystallization buffer: 0.2 M ammonium sul-
fate, 0.1 M sodium acetate pH 5.5, and 10% (wt/vol) PEG 2000
MME. For each crystallization condition, manual drops were set
up by adding 1.5 μL of protein solution and 1.5 μL of crystalli-
zation buffer against 500 μL of crystallization buffer in the well.
Crystals grew for 7 d and were mounted after soaking for 1 min in
crystallization buffer supplemented with 25% (vol/vol) glycerol.
Crystallographic Data Collection, Processing, Phasing, and Refinement.
All diffraction data were collected on beamline 21-ID-F (Life
Sciences Collaborative Access Team, Advanced Photon Source)
using a MAR Mosaic 225 detector. Datasets were obtained from
frozen, loop-mounted single crystals at 100 K using an oscillation
range of 1° and reduced using the HKL 2000 software suite.
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All structures were solved using by molecular replacement in
PHENIX (66) using models that were initially based off the
structure of C. crescentus ChpT (33). All model building and re-
finements were conducted using Coot and PHENIX, which are
maintained by the SBGrid consortium (67). Coordinates of the
B. abortus ChpT (PDB ID code 4QPK) and the 2:2 ChpT–CtrA
complex (PDB ID code 4QPJ) have been deposited in the Protein
Data Bank.
CD Spectroscopy. Protein samples for CD spectroscopy were pu-
rified as described above, dialyzed overnight in CD buffer (25 mM
Na phosphate pH 7.6 and 50 mM NaCl) and diluted to a final
concentration of 25 μM in CD buffer. Samples were analyzed using
a 1 mM cuvette on an Aviv 202 CD spectrometer. Data shown are
the average of three separate spectral scans.
ChpT–ATP Binding Measurements Using ITC. Proteins for ITC anal-
ysis were purified as detailed above and dialyzed overnight against
ITC buffer (25 mMTris pH 7.6, 125 mMNaCl, and 1 mMMgCl2)
and concentrated using Amicon Ultra 3k MWCO spin columns.
Samples were subsequently purified further using a HiPrep 26/60
Sephacryl S-200 (GE) gel-filtration column equilibrated in ITC
buffer and again dialyzed overnight against ITC buffer.
All binding measurements were performed using aMicroCal200
iTC (GE). All solutions and samples were extensively degassed.
The cell of the MicroCal200 iTC was filled with ChpT at con-
centrations of 200 μM (monomer). ChpT protein concentrations
were determined using the calculated extinction coefficient of
ChpT. The syringe was filled with 1 mM ATP (Sigma-Aldrich)
resuspended in ITC buffer. Titrations were initially performed at
25 °C with constant stirring. To confirm that the absence of ob-
served binding between ChpT and ATP was not due to high-affinity
binding reactions with ΔH values near 0, we performed sepa-
rate ITC experiments at 16 °C (where there was also no ap-
parent binding).
MD Simulations. Fully atomistic models of ChpT, CtrA, and the
ChpT–CtrA complex were constructed based on the crystallo-
graphic data presented in this study. Missing side chains were
added to the models using a least-squares fit to the backbone
atoms when necessary. All simulations were run with the Gro-
macs MD package, version 4.6.5 (71). Each structure was sol-
vated in TIP3 water with Na+ and Cl− counter ions to achieve a
neutral periodic cell at 150 mM concentration. The Amber99sb-
ILDN forcefield was used (72). The systems contained 95,606,
20,830, and 157,620 atoms, respectively. Each system was
energy-minimized using a gradient descent method to remove
high-energy contacts between the protein and the solvent and
relax any steric clashes. All bonds were replaced by constraints
using the LINCS algorithm (73). To equilibrate the systems, 10-ns
simulations in the NPT ensemble were performed at 300 K, using
the Parrinello–Rahman barostat at a pressure of 1 bar (74).
Samples were collected from simulations of the NVT ensemble,
which was maintained by a Nosé–Hoover thermostat with a ref-
erence temperature of 300 K. The simulations were run for 1,851,
1,000, and 886 ns, respectively. A 5-fs time step was used in all
production simulations. Electrostatics were evaluated every four
time steps using the particle mesh Ewald method (75).
SAXS. SAXS data on ChpT were collected at the Advanced
Photon Source beamline 18-ID (BioCAT, Argonne National
Laboratory). Purified ChpT was suspended in 25 mM Tris pH 7.6
and 125 mM NaCl at a concentration of 15 μM. Data were
collected using an Aviex CCD detector and analyzed in IgorPro.
LM and CryoEM of B. abortus. Brucella cells were grown in rich media
for the indicated time and fixed with 4% (vol/vol) paraformaldehyde
in PBS for 30 min. Samples were washed two times in PBS and
suspended in EM imaging buffer (20 mM Tris pH 7.6, 50 mM
glucose, and 10 mM EDTA) and samples were confirmed to
contain no viable cells, following established BSL3 B. abortus
protocols at the University of Chicago Ricketts Laboratory. Phase-
contrast images of cells were collected using a Leica DM 5000B
microscope with an HCX PL APO 63×/1.4 N.A. Ph3 objective.
Images were acquired with a mounted Orca-ER digital camera
(Hamamatsu) controlled by the Image-Pro software suite (Media
Cybernetics).
From visualization by cryoEM fixed cells were mixed with
BSA-treated 10 nm colloidal gold solution to avoid aggregation
(76). Three to four microliters of a cell culture–gold solution
mixture were applied to glow discharged copper Quantifoil
grids (Quantifoil Micro Tools). The grids were blotted either
manually or automatically using the Vitrobot (FEI) and plunged
into a liquid ethane/propane mixture (76, 77). The grids were
kept in liquid nitrogen until they were loaded into a Gatan 626
cryoholder and examined on an FEI T12 electron microscope at
120 keV.
Analysis of Brucella Cell Shape and DNA Content. Cells analyzed by
LM and flow cytometery were first grown to the indicated time in
rich media, fixed, and removed fromBSL3 containment as detailed
above. Phase-contrast images were obtained as detailed as above
and uniformly thresholded using ImageJ (78). Cell contours were
extracted and cell area analyzed using the open source Celltool
application (31). The following numbers of cells were analyzed for
cell shape analysis: WT (n = 611), ΔcpdR (n = 1,395), ctrA(V148F)
(n = 216), chpT++ (n = 140), chpT(E36R)++ (n = 261),
cpdR(WT)++ (n = 321), and cpdR(D52A)++ (n = 113).
Flow cytometery to measure DNA content was performed on a
BDFACSAria II cytometer. Propidium iodide was added (10 μg/mL
final) to 1 mL of fixed cells before analysis by flow cytometery. Data
for 20,000 individual cells were collected and analyzed using the
FlowJo software suite (FlowJo Enterprise).
THP1 Macrophage Infection Assays. Human monocytic THP-1 cells
(ATCC TIB-202) were maintained by culture in RPMI-1640
supplemented with 10% (vol/vol) heat-inactivated FBS and 2 mM
L-glutamine. For monocytic differentiation of THP-1 cells, 1 × 105
cells in RPMI supplemented with phorbol ester 12-O-tetradeca-
noylphorbol-13-acetate (40 μg·mL−1) were added to a each well of
96-well plate, and cells were grown for 24–48 h before proceed-
ing with infections. All THP-1 cells were grown at 37 °C with 5%
(vol/vol) atmospheric CO2.
For infections, B. abortus cells were resuspended in warmed
RPMI and added at an MOI of 100 cfu per macrophage cell. To
synchronize infections after the addition of Brucella cells, plates
were centrifuged at 200 × g for 5 min. After a 30-min incubation,
media was removed and replaced with RPMI supplemented with
100 μg·mL−1 gentamycin to kill extracellular bacteria. Afterward,
samples were incubated for 1 h, after which monolayers were
washed with PBS and THP-1 cells were lysed by addition of
0.01% Triton X-100. Serial dilutions were prepared and viable
cells were determined by plating on TSA plates. For longer time
points, the RPMI was removed and replaced with RPMI sup-
plemented with 50 μg·mL−1 gentamycin. Additional samples
were lysed as above and serial dilutions plated. All THP-1 assays
were performed in triplicate using independent B. abortus cul-
tures. The results presented illustrate the mean ± the SEM. For
THP-1 cell infections at the ctrA(V148F) permissive growth
temperature of 30 °C, THP-1 cells were initially prepared as
above, but after infections cells were grown at 30 °C with 5%
(vol/vol) atmospheric CO2.
Western Blot Analysis of CtrA Levels. For Western blot analysis,
overnight cultures of B. abortus were diluted to OD600 of 0.1 and
cultured for 4 h after shift to the nonpermissive growth condition
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or addition of IPTG as indicated. Five milliliters of cultures were
spun down and resuspended in 4× SDS-loading buffer treated
with DNaseI and 15 μL was resolved by SDS/PAGE. Primary
CtrA polyclonal antiserum was a gift from Peter Chien, University
of Massachusetts, Amherst, MA, and Brucella α-PhyR polyclonal
antiserum was used as a loading control. α-Rabbit antibody was
used as a secondary, which was conjugated to Alexa 488 (Life
Technologies).
RNA Isolation and qRT-PCR. RNA was extracted following a pre-
viously published method (65) after 4 h of growth at the non-
permissive temperature or IPTG addition in rich medium (starting
at an OD600 = 0.1). cDNA was generated using the SuperScript III
cDNA kit (Invitrogen) and qPCR was carried out using a SYBR
Green PCR kit (Life Technologies). Relative quantification of the
ccrM transcript was calculated using the 2−ΔΔCt method, using
rplK as the reference gene.
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Fig. S1. (A) Genome context of cckA (green), chpT (blue), ctrA (red), and cpdR (yellow) in B. abortus strain 2308. Locus numbers are indicated above each
gene. Percent amino acid sequence identity to C. crescentus orthologs is indicated below each gene. (B) Domain organization of B. abortus CckA, ChpT, CtrA,
and CpdR proteins. All proteins are drawn to scale. (C) C. crescentus and B. abortus ChpT phosphotransferase proteins aligned with the sequences of HKs E. coli
EnvZ and T. maritima HK853. Residues involved in protein dimerization (blue circles) and interaction with CtrA(C) (small red arrow) and CtrA(D) (small red star)
are indicated. The conserved histidine phosphorylation site is highlighted red. (D) Alignment of B. abortus CtrA, CpdR, CckA, and T. maritima RR468 REC
domains. Site of aspartyl phosphorylation is highlighted red. Residues that interact with ChpT(A) (small blue arrow) and ChpT(B) (small blue star) are indicated.
All secondary structure is indicated above the sequence (spiral, helix; horizontal arrow, beta strand).
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Fig. S2. Cryoelectron micrographs of B. abortus (A) ctrA(V148F), (B) chpT++, and (C) cpdR(D52A)++ overexpression strains. (D) Western blot of HA-tagged ChpT
and ChpT(E36R) proteins from B. abortus cell lysate resolved by SDS/PAGE. WT B. abortus cell lysate was run and blotted as a negative control.
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Fig. S3. qRT-PCR analysis of ccrM transcript levels in WT, ctrA(V148F), chpT++, EV++ (empty vector control), cpdR(WT)++, and cpdR(D52A)++ backgrounds. ccrM
transcript levels in each independent strain sample (n = 3) are normalized to the WT mean, which is set to a value of 1.
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Fig. S4. (A) Guinier fit of B. abortus ChpT SAXS data. (B) ITC assay of ChpT titrated with ATP. Isotherms at 16 °C and 25 °C indicate no apparent binding
(>1 mM equilibrium affinity) between ChpT and ATP. (C) CD spectra of purified WT ChpT and mutant alleles of ChpT. (D) Coomassie-stained SDS polyacrylamide
gel of purified proteins used in Fig. 2. (E) [32P]acetyl phosphate labeling of purified B. abortus receiver (REC) domains.
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Fig. S5. (A) Simulated annealing composite omit map (contoured at ±2σ) of a region surrounding a glycerol molecule (GOL; colored green) in the binding
pocket of the ChpT CA domain. (B) Interaction map of polar contacts between ChpT monomers (A and B; blue) and CtrAREC domains (C and D; red), hydrogen
bonds (black lines), and salt bridges (dotted red lines). Magnified view of ChpT–CtrA complex structure showing (C) ChpT(A)–CtrA(C) and (D) ChpT(B)–CtrA(D)
interacting residues.
Table S1. Deletion statistics for the essential B. abortus chpT
and cckA genes
Strain Results of chpT deletion
WT sacB inactivation ΔchpT
2308 81 17 0
2308 PchpT-chpT 57 6 8
Results of cckA deletion
WT sacB inactivation ΔcckA
2308 58 42 0
2308 PcckA-cckA 41 37 21
Gene deletion by double-crossover recombination, using sacB counter se-
lection on sucrose, was attempted in WT B. abortus strain 2308 in the absence
(n = 98 total colonies screened) and presence (n = 71 total colonies screened)
of a complementing copy of chpT on a replicating plasmid (PchpT-chpT).
Deletion of cckA was attempted on WT B. abortus strain 2308 in the absence
(n = 100 total colonies screened) and presence (n = 99 total colonies screened)
of a complementing copy of cckA on a replicating plasmid (PcckA-cckA). The
table reports the number of colonies identified as WT revertants after sucrose
counterselection (WT), the number of colonies with random sacB inactiva-
tion, and the number of colonies harboring an in-frame deletion of chpT
(ΔchpT) or cckA (ΔcckA). We only identified colonies harboring an in-frame
deletion when the complementing copy of chpT or cckA was present.
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Table S2. Crystallographic data and refinement statistics
Statistics ChpT ChpT–CtrA
Data collection statistics
Resolution range, Å 35.42–1.66 (1.719–1.66) 17.88–2.742 (2.839–2.742)
Unique reflections 50,679 (5,049) 32,556 (3,179)
Rmerge 0.043 0.086
I/σI 27.66 (2.68) 23.30 (2.52)
Redundancy 7.5 11.8
Completeness, % 99.96 (100.00) 99.80 (98.03)
Refinement statistics
Space group P 43 P 3221
Unit cell 70.84 70.84 87.01 (90 90 90) 124.951 124.951 136.332 (90 90 120)
Rfree reflections 3,925 2,007
Rwork 0.1624 (0.2455) 0.1753 (0.2337)
Rfree 0.1906 (0.2620) 0.2216 (0.2875)
Average B-factor 27.3 65.4
RMS (bonds) 0.007 0.009
RMS (angles) 1.11 1.22
Ramachandran analysis
Favored, % 98.3 98.0
Allowed, % 1.7 1.8
Outliers, % 0.0 0.2
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Table S3. Strains used in this study
FC no. E. coli strain Notes
2271 Rosetta / pET28a-RR0099 Expresses soluble REC domain - Bab1_0099
2272 Rosetta / pET28a-RR0136 Expresses soluble REC domain - Bab1_0136
2273 Rosetta/pET28a-RR0345 Expresses soluble REC domain - Bab1_0345
2274 Rosetta/pET28a-RR0370 Expresses soluble REC domain - Bab1_0370
2275 Rosetta/pET28a-RR0628 Expresses soluble REC domain - Bab1_0628
2276 Rosetta/pET28a-RR0636 Expresses soluble REC domain - Bab1_0636
2277 Rosetta/pET28a-RR1138 Expresses soluble REC domain - Bab1_1138
2278 Rosetta/pET28a-RR1140 Expresses soluble REC domain - Bab1_1140
2279 Rosetta/pET28a-RR1538 Expresses soluble REC domain - Bab1_1538
2280 Rosetta/pET28a-RR1614 Expresses soluble REC domain - ctra - Bab1_1614
2281 Rosetta/pET28a-RR1671 Expresses soluble REC domain - Bab1_1671
2282 Rosetta/pET28a-RR2006 Expresses soluble REC domain - Bab1_2006
2283 Rosetta/pET28a-RR2092 Expresses soluble REC domain - Bab1_2092
2284 Rosetta/pET28a-RR2146 Expresses soluble REC domain - Bab1_2146
2285 Rosetta/pET28a-RR0041 Expresses soluble REC domain - cpdr - Bab2_0041
2286 Rosetta/pET28a-RR0042 Expresses soluble REC domain - Bab2_0042
2287 Rosetta/pET28a-RR0081 Expresses soluble REC domain - Bab2_0081
2288 Rosetta/pET28a-RR0222 Expresses soluble REC domain - Bab2_0222
2289 Rosetta/pET28a-RR0628 Expresses soluble REC domain - Bab2_0628
2290 Rosetta/pET28a-RR0630 Expresses soluble REC domain - Bab2_0630
2291 Rosetta/pET28a-RR0762 Expresses soluble REC domain - Bab2_0762
2292 Rosetta/pET28a-RR0806 Expresses soluble REC domain - Bab2_0806
2293 Rosetta/pET28a-RR1099 Expresses soluble REC domain - Bab2_1099
2294 Rosetta/pET28a-chpT Expresses full-length chpt - Bab1_1613
2295 Rosetta/pET28a-chpT(N33A,E36A,E40A) Site-directed mutant of FC2294
2296 Rosetta/pET28a-chpT(K96A,R156A,H177A) Site-directed mutant of FC2294
2297 TOP10/pNPTS138::ctrA(V148F) For making V148F mutant in Brucela
2298 Rosetta/pET28a-chpT(N33R) Site-directed mutant of FC2294
2299 Rosetta/pET28a-chpT(E36R) Site-directed mutant of FC2294
2300 Rosetta/pET28a-chpT(E40R) Site-directed mutant of FC2294
2301 Rosetta/pET28a-ctrA(S15R) Site-directed mutant of FC2280
2302 Rosetta/pET28a-cpdR(F16R) Site-directed mutant of FC2285
2303 Rosetta/pET28a-cckAsoluble Expresses soluble fragment of ccka
CBA no. Brucella strain
21 B. abortus 2308 WT Brucella strain
25 2308 pSRK- WT Brucella with empty pSRK plasmid
113 2308 pSRK-chpT WT Brucella expressing chpT-WT from pSRK
114 2308 pSRK-chpT(E36R) WT Brucella expressing chpT(E36R) from pSRK
115 2308 ctrA(V148F) Temperature-sensitive allele of ctrA
116 2308 pSRK-cpdR(WT) WT Brucella expressing cpdR-WT
117 2308 pSRK-cpdR(D52A) WT Brucella expressing cpdR-D52A
“FC” and “CBA” refer to S.C. laboratory strain prefixes.
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Table S4. Primers used in this study
Name Sequence 5′→3′ Notes
RR0099-BamHI F AAGGATCCTTGATGAACGATCTCGAACATAGG BAB1_0099; for cloning BamHI/HindIII
fragment into pET28a for
overexpression; FL protein
RR0099-HindIII R AAAGCTTTCAGGCGACGCTGGATGA
RR0136 - BamHI - F GGATCCATGGAAGACTTGAAGCA BAB1_0136 - for cloning BamHI/HindIII
fragment into pET28a
for overexpression
RR0136 - HindIII - R AAGCTTTCAGCGCGGCGCGCGCT
RR0345 - BamHI- F GGATCCATGCATTTCATTATCGC BAB1_0345 - for cloning BamHI/HindIII
fragment into pET28a for overexpression;
amino acids 1–121
RR0345 - HindIII - R AAGCTTtcaGCCGGCAAGCACCGCACCCA
RR0370 - BamHI - F GGATCCATGACGAATGAATGCAA BAB1_0370; for cloning BamHI/HindIII
fragment into pET28a for overexpression;
amino acids 1–126
RR0370 - HindIII - R AAGCTTtcaGCCGGAGGCGACGGCAT
RR0628 - BamHI - F GGATCCTTGCGTATCCTGATTGTTGA BAB1_0628; for cloning BamHI/HindIII
fragment into pET28a for overexpression;
amino acids 1–120
RR0628 - HindIII - R AAGCTTtcaGGCAGCACGGCGGATCA
RR0636 - BamHI - F GGATCCATGAAAATTCTCGTTATC BAB1_0636; for cloning BamHI/HindIII
fragment into pET28a for overexpression;
amino acids 1–118
RR0636 - HindIII - R AAGCTTtcaGCGGCGCTGCAAGACCTCGACAC
RR1138 - BamHI - F GGATCCATGGCGGCCGATATTCT BAB1_1138; for cloning BamHI/HindIII
fragment into pET28a for overexpression;
amino acids 1–120
RR1138 - HindIII - R AAGCTTtcaGGTTTCCAGCGCCCGTT
RR1140 - BamHI - F GGATCCATGATTGCAGGGCGTCCGA BAB1_1140; for cloning BamHI/HindIII
fragment into pET28a for overexpression:
amino acids 1–120
RR1140 - HindIII - R AAGCTTtcaTTCCGAGAGCGCGCGCC
RR1538 - BamHI - F GGATCCATGGGATCGAAAGACGC BAB1_1538; for cloning BamHI/HindIII
fragment into pET28a for overexpression;
amino acids 1–137
RR1538 - HindIII - R AAGCTTtcaACGGCGCAGGATATTGT
RR1614 - BamHI -F GGATCCATGCGCGTCCTTTTGAT BAB1_1614; for cloning BamHI/HindIII
fragment into pET28a for overexpression;
amino acids 1–118
RR1614 - XhoI - R CTCGAGtcaGCGGCGGACGATCGCATGGATACGG
RR1671 - BamHI - F GGATCCCGTCTGATGATCATTGAGGATG BAB1_1671; for cloning BamHI/XhoI
fragment into pET28a for overexpression;
amino acids 141–264
RR1671 - XhoI - R CTCGAGTCAGGCAGCAACTTGCGA
RR2006 - BamHI - F GGATCCATGACAGGCCGTACTAT BAB1_2006; for cloning BamHI/XhoI
fragment into pET28a for overexpression;
amino acids 1–122
RR2006 - XhoI - R CTCGAGtcaCTGGCGCAACTGCGCGC
RR2092 - BamHI - F GGATCCATGAAGGAAGCTTCGGC BAB1_2092; for cloning BamHI/XhoI
fragment into pET28a for overexpression;
amino acids 1–128
RR2092 - XhoI - R CTCGAGtcaGCGCGCCGCCACGCGGC
RR2146 - BamHI - F GGATCCATGTCCCAAGTACCCCGA BAB1_2146; for cloning BamHI/HindIII
fragment into pET28a for overexpression;
amino acids 1–124
RR2146 - HindIII - R AAGCTTtcaCGCCTTGACGCGGGCAA
RR0041 - BamHI - F GGATCCATGAACTGCGCATATGA BAB2_0041; for cloning BamHI/HindIII
fragment into pET28a for overexpression;
amino acids 1–126
RR0041- HindIII - R AAGCTTtcaTGTCCGGATCGCCTGTT
RR0042- BamHI - F GGATCCATGAAGAGAATCCTTCTAGCTGA BAB2_0042; for cloning BamHI/HindIII
fragment into pET28a for
overexpression; FL protein
RR0042 - HindIII - R AAGCTTTCAGGCGGCGATCAGCA
RR0081 - BamHI -F GGATCCATGGCAACGCGCATTCT BAB2_0081; for cloning BamHI/HindIII
fragment into pET28a for overexpression;
amino acids 1–121
RR0081 - HindIII - R AAGCTTtcaGAGTTTCAACACATTTGC
RR0222 - BamHI - F GGATCCATGAGAATTATCCTCAT BAB2_0222; for cloning BamHI/HindIII
fragment into pET28a
for overexpression
RR0222- HindIII - R AAGCTTtcaGCGCCGCGCTACCGCGT
RR0628 - BamHI -F GGATCCATGACGAAAAGCGTAAT BAB2_0628; for cloning BamHI/HindIII
fragment into pET28a for overexpression;
FL protein
RR0628 - HindIII - R AAGCTTCTAGGCATCGCCCAGAT
RR0630 - BamHI - F GGATCCATGACAGCAAGGATTCTCGTCG BAB2_0630: for cloning BamHI/XhoI
fragment into pET28a for
overexpression: For amplification
of both REC domains together
RR0630 - XhoI - R CTCGAGtcaGCGCTTGATCTGTGTGC
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Table S4. Cont.
Name Sequence 5′→3′ Notes
RR0762 - BamHI - F GGATCCTTGAAAGAAGACGCCCACATTC BAB2_0762; for cloning BamHI/HindIII
fragment into pET28a for overexpression;
amino acids 1–121
RR0762 - HindIII - R AAGCTTtcaACGGCGAAGCACGGCGC
RR0806 - BamHI - F GGATCCATGAATATTTCTCCACA BAB2_0806; for cloning BamHI/HindIII
fragment into pET28a for overexpression;
amino acids 1–157
RR0806 - HindIII - R AAGCTTtcaGCCAGCCATGGCAAGCCGA
RR1099 - BamHI - F GGATCCATGATTGTTGTCGTTGACGACA BAB2_1099; for cloning BamHI/HindIII
fragment into pET28a for overexpression;
amino acids 1–106
RR1099 - HindIII - R AAGCTTtcaGCGGACATGAACGGGCTT
Hpt1613 - BamHI - F GGATCCATGTCCTTGCCCGTTAC Bab1_1613, ChpT; for cloning BamHI/HindIII
fragment into pET28a for overexpression;
expresses entire protein
Hpt1613 - Hindiii - R AAGCTTTCATTCCGCGGAAAAGACGATAT
dHpt1613-Up-BamHI-F GGATCCAGCGATGAAGGAGACAAACAGA For deletion of B. abortus Hpt 1613
dHpt1613-Up-R ccgcggaCAAGGACATGGCGCTTT
dHpt1613-Dn-F ATGTCCTTGTCCGCGGAATGAATTGA
dHpt1613-Dn-SalI-R AAGTCGACACGATTATATGACCAAG
CckA-kinase only-BamHI-F ATATGGATCCGCGCTGGAAAACCAGAT For cloning BamHI/HindIII fragment
into pET28a for overexpression;
for soluble form of CckA
CckA-FL-HindIII-R ATATAAGCTTTCAATCCTGTTTCTCCAG
ChpT-F-NdeI-Brucella-o/E TATACATATGTCCTTGCCCGTTAC Site-directed mutagenesis primers
ChpT-R-KpnI-Brucella-o/E ATATGGTACCTCATTCCGCGGAAAAGACGATAT
ChpT-E40A-R catcggcgccacctgcttccagcaattcc
ChpT-E40A-F ggaattgctggaagcaggtggcgccgatg
ChpT-N33A,E36A-R cttcttccagcaatgccagaccagcattgatcgcaccgaccggt
ChpT-N33A,E36A-F accggtcggtgcgatcaatgctggtctggcattgctggaagaag
ChpT-K96A-R aggtgaattccggcgcttcgttcctgaaatattcagtggcga
ChpT-K96A-F tcgccactgaatatttcaggaacgaagcgccggaattcacct
ChpT-R156A-R cggcggcacggctagcatccggcctttgac
ChpT-R156A-F gtcaaaggccggatgctagccgtgccgccg
ChpT-H177A-R gggctgtacggaagcggcgtcgatgggc
ChpT-H177A-F gcccatcgacgccgcttccgtacagcc
chpT-R-HA+XbaI tctagaTCAAGCGTAATCTGGAACATCGTATGGGTATTCCGCG-
GAAAAGACGATAT
CtrA-V148F-R ccggtcagatgaaagcgctggcctgcg
CtrA-V148F-F cgcaggccagcgctttcatctgaccgg
ChpT-N33R-R gcaattccagacccctattgatcgcaccgaccggtgag
ChpT-N33R-F ctcaccggtcggtgcgatcaataggggtctggaattgc
ChpT-E36R-R gccaccttcttccagcaatctcagaccattattgatcgca
ChpT-E36R-F tgcgatcaataatggtctgagattgctggaagaaggtggc
ChpT-E40R-R atcggcgccacctctttccagcaattccagaccattattg
ChpT-E40R-F caataatggtctggaattgctggaaagaggtggcgccgat
ctrA-s15R-R ttgagcatcaactcaatcctctgtgcgatagcact
ctrA-s15R-F agtgctatcgcacagaggattgagttgatgctcaa
cpdR-F16R-R ccagcgcttttacgaggcgacggcgcatatcgttatcg
cpdR-F16R-F cgataacgatatgcgccgtcgcctcgtaaaagcgctgg
rplK_qPCR_F CCGGTGACCTACTTCCTCAA Housekeeping control for qPCR
rplK_qPCR_R ATCGAACGGGCAGAACCT
ccrM_qPCR_F GGCTCGACTCCATCATCAAA For qPCR to analyze B. abortus
ccrM (bab1_0516). Yields
109-bp PCR product
ccrM_qPCR_R CCGCCAAGCTGGAGATTATAG
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